<DOC>
	<DOC>NCT01459250</DOC>
	<brief_summary>This study will assess the pharmacokinetics, safety and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in healthy matched control subjects.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Mild, moderate, severe renally impaired or ESRD patients. Healthy male or female subjects to match renally impaired patients in BMI (±15%), age (± 7 years) and gender (in this order). Smoking status (yes or no) will also be used as a final criterion, if deemed feasible by the Investigator. Pregnant or nursing (lactating) women Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless using effective contraception during the study as defined in the protocol. Smokers, smoking 10 cigarettes or more per day from screening to study completion Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study Comedication for healthy subjects Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>AGO178C,</keyword>
	<keyword>renal impairment,</keyword>
	<keyword>ESRD,</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>